Cosciens Biopharma (CSCI) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
17 Jun, 2026Opening remarks and agenda
Meeting opened with introductions of the board and explanation of virtual meeting procedures, including Q&A and voting protocols.
Agenda included presentation of financial statements, auditor appointment, board elections, and a special resolution on share consolidation and split.
Board and executive committee updates
Six directors were nominated for re-election, all confirmed their willingness to serve and were eligible under corporate bylaws.
Shareholder proposals
Special resolution proposed for a share consolidation (1 for 150) followed by a share split (50 for 1), with cash-out for holders of fewer than 150 shares at $1.60 per share.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cosciens Biopharma
- Returned to profitability in Q1 2026, driven by discontinued operations and lower expenses.CSCI
Q1 202612 May 2026 - Restructuring and subsidiary exit drove lower losses and improved cost structure in 2025.CSCI
Q4 202525 Mar 2026 - Six directors elected, auditor reappointed, and company name change approved; no questions asked.CSCI
AGM 20243 Feb 2026 - Operating expenses fell 59% and net loss narrowed in Q3 2025 amid restructuring and Nasdaq delisting.CSCI
Q3 202512 Nov 2025 - Q2 2025 saw revenue growth, cost cuts, Nasdaq delisting, and major leadership changes.CSCI
Q2 202514 Aug 2025 - Q3 2024 net loss widened on higher R&D and merger costs; new product launches on track.CSCI
Q3 202413 Jun 2025 - Revenue rose but net loss widened due to higher R&D and SG&A costs; DETECT trial data expected Q3.CSCI
Q2 202413 Jun 2025 - Revenue up 35% but net loss deepened as COSCIENS pivots to natural-based products.CSCI
Q4 20246 Jun 2025 - Net loss widened in Q1 2025 as COSCIENS advanced clinical and nutraceutical initiatives.CSCI
Q1 20256 Jun 2025